Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 706-715

  Pantazopoulos, Ioannis ^a   Boura, Paraskevi ^b   Xanthos, Theodoros ^b   Syrigos, Konstantinos ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Asbestos; Megakaryocyte potentiating factor; Soluble mesothelin related peptides

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; BIOLOGICAL MARKER; CA 125 ANTIGEN; CYTOKERATIN 19; CYTOKINE; HYALURONIC ACID; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; OSTEOPONTIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL PRACTICE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; MALIGNANT MESOTHELIOMA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; OCCUPATIONAL EXPOSURE; OVERALL SURVIVAL; PATIENT MONITORING; PLEURA FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FAMILY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; URINE LEVEL;

ASBESTOS; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; OSTEOPONTIN; PLEURA; PLEURAL NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84875245767     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00226111     Document Type: Review

References (71)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
2. Le GV, Takahashi K, Park EK, et al. Asbestos use and asbestosrelated diseases in Asia: Past, present and future. Respirology 2011; 16: 767-775.
3. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008; 14: 303-309.
4. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418.
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
6. Klebe S, Henderson DW. Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 2011; 189: 169-193.
7. Ray M, Kindler HL. Malignant pleural mesothelioma: An update on biomarkers and treatment. Chest 2009; 136: 888-896.
8. Alataş F, Alataş O, Metintaş M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
9. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140.
10. Watanabe H, Okada G, Ohtsubo K, et al. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas 2005; 30: 349-354.
11. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006; 15: 1014-1020.
12. Bharadwaj U, Li M, Chen C, et al. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 2008; 6: 1755-1765.
13. Bharadwaj U, Marin-Muller C, Li M, et al. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011; 32: 1013-1024.
14. Bharadwaj U, Marin-Muller C, Li M, et al. Mesothelin confers pancreatic cancer cell resistance to TNF-a-induced apoptosis through Akt/PI3K/NF-kB activation and IL-6/Mcl-1 overexpression. Mol Cancer 2011; 10: 106.
15. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: A potential test for malignant pleural mesothelioma. Clin Chem 2007; 53: 666-672.
16. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-5081.
17. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein-a blood test for mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S109-S111.
18. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009; 18: 646-650.
19. Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010; 181: 620-625.
20. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851-857.
21. Hollevoet K, Nackaerts K, Thas O, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012; 141: 477-484.
22. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85: 265-272.
23. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
24. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-1160.
25. Creaney J, Musk AW, Robinson BW. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol 2010; 5: 1461-1466.
26. Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008; 3: 1317-1324.
27. Azim HA Jr, Gaafar R, Abdel Salam I, et al. Soluble mesothelinrelated protein in malignant pleural mesothelioma. J Egypt Natl Canc Inst 2008; 20: 224-229.
28. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-2935.
29. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: A useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62: 569-576.
30. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007; 132: 1239-1246.
31. Iwahori K, Osaki T, Serada S, et al.Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin. Lung Cancer 2008; 62: 45-54.
32. Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumourassociated markers for early detection of malignant mesothelioma: An epidemiological study. Cancer Epidemiol Biomarkers Prev 2008; 17: 163-170.
33. Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009; 180: 437-444.
34. Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1587-1593.
35. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: 447-453.
36. Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009; 179: 950-954.
37. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelinrelated peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28: 3316-3322.
38. Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: Relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011; 17: 1181-1189.
39. Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 2011; 6: 1930-1937.
40. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: The dust diseases board cohort study. Am J Respir Crit Care Med 2008; 178: 832-837.
41. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study. Lung Cancer 2008; 61: 235-243.
42. Gube M, Taeger D, Weber DG, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 2011; 85: 185-192.
43. Hollevoet K, Van Cleemput J, Thimpont J, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: A prospective longitudinal cohort study. J Thorac Oncol 2011; 6: 889-895.
44. Creaney J, Olsen NJ, Brims F, et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2238-2246.
45. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7: 147-154.
46. Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011; 49: 1721-1726.
47. Badgwell D, Lu Z, Cole L, et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG-free b subunit and urinary hCG b core fragment. Gynecol Oncol 2007; 106: 490-497.
48. Ordónez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197.
49. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006; 97: 928-932.
50. Yamaguchi N, Hattori K, Oheda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994; 269: 805-808.
51. Wang T, Kajino K, Abe M, et al. Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. Int J Mol Med 2010; 26: 185-191.
52. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12: 4225-4231.
53. Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008; 14: 1431-1437.
54. Tajima K, Hirama M, Shiomi K, et al. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res 2008; 28: 3933-3936.
55. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573.
56. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-1881.
57. Cullen MR. Serum osteopontin levels-is it time to screen asbestos-exposed workers for pleural mesothelioma?N Engl J Med 2005; 353: 1617-1618.
58. Cristaudo A, Foddis R, Bonotti A, et al. Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 2010; 25: 164-170.
59. Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 2011; 74: 55-60.
60. Grigoriu B, Chahine B, Zerimech F, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009; 42: 1046-1050.
61. van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: The role of tumour markers. Lung Cancer 2008; 59: 350-354.
62. Boudville N, Paul R, Robinson BW, et al. Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011; 73: 320-324.
63. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009; 55: 1431-1433.
64. Park EK, Thomas PS, Creaney J, et al. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010; 48: 869-874.
65. Cristaudo A, Foddis R, Bonotti A, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67: 233-236.
66. Tan K, Kajino K, Momose S, et al. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Hum Pathol 2010; 41: 1330-1338.
67. Nelson HH, Almquist LM, LaRocca JL, et al. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Epigenetics 2011; 6: 1029-1034.
68. Shiomi K, Shiomi S, Ishinaga Y, et al. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin. Anticancer Res 2011; 31: 1427-1430.
69. Foddis R, Vivaldi A, Guglielmi G. Serum osteopontin levels in previously asbestos-exposed workers. G Ital Med Lav Ergon 2006; 28: 426-428.
70. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541-1549.
71. van Klaveren RJ, Aerts JG, de Bruin H, et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43: 63-69.